New hope for hard-to-treat lung cancer: drug duo targets KRAS mutation
NCT ID NCT07339839
First seen Jan 20, 2026 · Last updated May 16, 2026 · Updated 15 times
Summary
This study tests two experimental drugs, Glecirasib and Ivonescimab, together as a first treatment for people with a specific type of advanced lung cancer (KRAS G12C mutation, PD-L1 positive). The goal is to see if the combination is safe and can shrink tumors. About 42 adults will take part. This is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12C are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.